Track the Paxman AB (publ) stock price and the full insider trade history of the company, a publicly traded company based in Finland. Shares trade on the FI market, under the oversight of FIN-FSA. Operating in the Health Care sector, Paxman AB (publ) has published 27 reports. Market capitalisation: €1.3bn. The latest transaction was reported on 26 August 2026 (Purchase). Among the most active insiders: Per-Anders Johansson. Every trade is openly available.
27
Insider Decl.
n/a
Thresholds
€812,120
23 ops.
Buy Volume
€12m
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Paxman AB (publ) Strong Buy (bullish), based on 2 analysts. Average price target: SEK 93.50.
38Σ signal
Buys €812,120€12m Sells
Fundamental score
Ranked 21,059 of 28,929 companies
36.4
score / 100
Value
22
Quality
51
FCF yld-1.2%
Earn yld-1.3%
EV/EBITDA44.9x
ROE-3.3%
Gross mgn67%
Net mgn-5.3%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,100 shares@ €7.11030.0084% mcap14.6% of flowAktieISINISIN SE0009806284FI:A003R939-1
25 of 27 declarations
About Paxman AB (publ)
Paxman AB (publ) is a Swedish company focused on developing solutions for managing the side effects of chemotherapy. It is listed on the Stockholm Stock Exchange (XSTO).